Whatman CEO leaves after less than two years
This article was originally published in Clinica
Howard Kelly is to step down as CEO of UK filtration, separations and DNA storage firm Whatman. He is the second chief to depart in as many years under the chairmanship of Bob Thian, who has overseen a rigorous rationalisation process since taking office in October 2002.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.